[go: up one dir, main page]

Leipold et al., 2018 - Google Patents

Comparison of CyTOF assays across sites: Results of a six-center pilot study

Leipold et al., 2018

View HTML
Document ID
17867035685687813569
Author
Leipold M
Obermoser G
Fenwick C
Kleinstuber K
Rashidi N
McNevin J
Nau A
Wagar L
Rozot V
Davis M
DeRosa S
Pantaleo G
Scriba T
Walker B
Olsen L
Maecker H
Publication year
Publication venue
Journal of immunological methods

External Links

Snippet

For more than five years, high-dimensional mass cytometry has been employed to study immunology. However, these studies have typically been performed in one laboratory on one or few instruments. We present the results of a six-center study using healthy control …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature

Similar Documents

Publication Publication Date Title
Leipold et al. Comparison of CyTOF assays across sites: Results of a six-center pilot study
Gadalla et al. Validation of CyTOF against flow cytometry for immunological studies and monitoring of human cancer clinical trials
Becht et al. High-throughput single-cell quantification of hundreds of proteins using conventional flow cytometry and machine learning
Subrahmanyam et al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Kleinsteuber et al. Standardization and quality control for high‐dimensional mass cytometry studies of human samples
Schulz et al. Single‐cell phospho‐protein analysis by flow cytometry
Bendall et al. Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development
Perez et al. Phospho‐proteomic immune analysis by flow cytometry: From mechanism to translational medicine at the single‐cell level
Leelatian et al. Characterizing phenotypes and signaling networks of single human cells by mass cytometry
Holmberg-Thyden et al. A user's guide to multicolor flow cytometry panels for comprehensive immune profiling
Bardet et al. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Kimmey et al. Parallel analysis of tri-molecular biosynthesis with cell identity and function in single cells
Mazza et al. Background fluorescence and spreading error are major contributors of variability in high‐dimensional flow cytometry data visualization by t‐distributed stochastic neighboring embedding
Kužílková et al. Standardization of workflow and flow cytometry panels for quantitative expression profiling of surface antigens on blood leukocyte subsets: an HCDM CDMaps initiative
Preglej et al. Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach
Bagwell et al. Human B‐cell and progenitor stages as determined by probability state modeling of multidimensional cytometry data
Baughn et al. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry
Ishiyama et al. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib
Bandyopadhyay et al. Analysis of signaling networks at the single-cell level using mass cytometry
Fox et al. Acquisition of high‐quality spectral flow cytometry data
Lamble et al. Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia
Jensen et al. Analytical performance of a 25‐marker spectral cytometry immune monitoring assay in peripheral blood
Byrd et al. Polystyrene microspheres enable 10‐color compensation for immunophenotyping of primary human leukocytes
Gupta et al. Evaluation of anticancer agents using flow cytometry analysis of cancer stem cells
Al Mamari et al. Measurement of hematopoietic progenitor cells using XN2000 hematology analyzer